Takeda Pharmaceutical Company Limited Board of Directors

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Mr. Christophe Weber

Mr. Christophe Weber

President, CEO & Representative Director

Mr. Iwaaki Taniguchi

Mr. Iwaaki Taniguchi

Senior Vice President of Corporate Finance & Controlling Department

Mr. Yoshihiro Nakagawa

Mr. Yoshihiro Nakagawa

Global General Counsel

Mr. Salvatore Alesci M.D., Ph.D.

Mr. Salvatore Alesci M.D., Ph.D.

Member of Management Board and Head of R&D Global Science & Biomedical Policy

Mr. Christopher David O'Reilly

Mr. Christopher David O'Reilly

Global Head of Investor Relations & Global Finance

Mr. Gabriele Ricci

Mr. Gabriele Ricci

Chief Data & Technology Officer

Mr. Haruhiko Hirate

Mr. Haruhiko Hirate

Member of Management Board

Norimasa Takeda

Norimasa Takeda

Chief Accounting Officer & Corporate Controller

Dr. Seigo Izumo

Dr. Seigo Izumo

Chair of Management Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.